Feed ANRO
AN
Alto Neuroscience, Inc. ANRO · NYSE
$22.85 +4.12% (+$0.91)
Summary
48 / 100 · Bulios Score
Valuation 49Growth -Profitability -Quality 37Debt 69Stability 41
What speaks for it
- It earns 18 USD a year on every 100 USD of invested capital.
- It holds more cash than debt: $243.7M against $7.05M.
What to watch
- It passes only 2 of the 9 points of the Piotroski financial health test.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Fairly pricedIs it growing?
Revenue (USD)
20212022202320242025
Diluted EPS (USD)
2021202220232024202520262027
- Analyst estimate
There is not enough revenue history yet to say how fast it grows.
Growth in detailDoes it make money?
Over the last 12 months it made a loss of $84.2M.
Profitability in detailIs it financially healthy?
YesCash and short-term investments $243.7M
Debt $7.05M
Free cash flow over 12 months -$68.8M
Over the last 12 months it spent more cash than it brought in. It holds more cash than debt.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 8
- Hold 1
- Sell 0
Today's price within the analysts' price targets
Today's price $22.85 Average target $38
$22.85 $55
The average target of $38 is 66% above today's price. 89% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
By product
The company reports no revenue by product.
By region
The company reports no revenue by region.